We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma.
- Authors
Lenz, G.; Tilly, H.; Ziepert, M.; Altmann, B.; Craine, V.; Yan, M.; Herbaux, C.; Frontzek, F.; Nickelsen, M.; Hirata, J.; Sahin, D.; Lee, C.; Morschhauser, F.; Schmitz, N.
- Abstract
Progression-free (PFS) and overall survival (OS) rates for young patients (18-60 years) with high-risk (age-adjusted IPI 2, 3) DLBCL treated with R-CHOEP were among the best reported for such patients. B Introduction: b The best treatment for young patients with high-risk diffuse large B-cell lymphoma (DLBCL) is still a matter of debate. Patients treated with R-CHOEP experienced more hematological toxicity and infections (29.9% >= grade 3 infections in R-CHOEP-treated vs. 15.0% in pola-R-CHP treated patients) with 4 treatment-related deaths occurring in patients treated with R-CHOEP and 2 treatment-related deaths following pola-R-CHP, respectively.
- Subjects
DIFFUSE large B-cell lymphomas
- Publication
Hematological Oncology, 2023, Vol 41, p420
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_308